CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:        
Research and development $ 11,948 $ 7,857 $ 27,573 $ 16,760
General and administrative 4,716 2,280 12,240 6,360
Total operating expenses 16,664 10,137 39,813 23,120
Loss from operations (16,664) (10,137) (39,813) (23,120)
Other income (expense):        
Research and development incentives 951 1,577 2,192 1,937
Investment income 550 882 1,804 1,775
Interest expense (834)   (1,029)  
Change in fair value of warrant liability       (5,452)
Other income (expense) (192) 5 10 682
Total other income (expense), net 475 2,464 2,977 (1,058)
Net loss attributable to common stockholders $ (16,189) $ (7,673) $ (36,836) $ (24,178)
Net loss per share attributable to common shareholders, basic and diluted (in dollars per share) $ (0.46) $ (0.24) $ (1.13) $ (1.18)
Weighted average common shares outstanding-basic and diluted (in shares) 34,877,944 31,577,313 32,742,148 20,433,580